Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy

@article{Gauthier2017ReducedintensityAN,
  title={Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy},
  author={Jordan Gauthier and Luca Castagna and Federico Garnier and Terr{\'e}e Guillaume and Gerald Socie and S{\'e}bastien Maury and Natacha Maillard and Reza Tabrizi and Tony Marchand and J V Malfuson and A Gac and Emmanuel Gyan and M{\'e}lanie Mercier and Yves Beguin and J{\'e}r{\'e}my Delage and Pascal Turlure and Antoine Marcais and St{\'e}phanie Nguyen and R{\'e}my Dul{\'e}ry and J Bay and Andrew Huynh and {\'E}tienne Daguindau and J. Cornillon and Caroline R{\'e}gny and M Michallet and R{\'e}gis Peffault de Latour and Ibrahim Yakoub-Agha and Dackouo Blaise},
  journal={Bone Marrow Transplantation},
  year={2017},
  volume={52},
  pages={689-696}
}
Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from… CONTINUE READING